What changed from existing technology?
This study found new long non-coding RNAs that are active in a specific type of breast cancer called TNBC basal subtype, which could help in diagnosing this aggressive cancer.
This study identifies three novel lncRNAs specifically associated with the TNBC basal subtype, which were not previously known to be linked to this cancer sub-type.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
sive type of breast cancer (BC). Considering this, our prospective study focuses on developing a lncRNA signature that can aid in the diagnosis of the TNBC subtype. Di
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The identified lncRNAs could potentially be used as biomarkers for the early detection or diagnosis of the TNBC basal subtype.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.